Gastric Bypass Surgery in India and UAE | Complete Patient Guide

• BMI ≥ 40 kg/m² without comorbidities, OR BMI ≥ 35 kg/m² with at least one obesity-related comorbidity (Type 2 diabetes, hypertension, obstructive sleep apnea, NAFLD/NASH, osteoarthritis, GERD)

• BMI ≥ 30–34.9 kg/m² with poorly controlled Type 2 diabetes or metabolic syndrome may qualify at selected centers under IFSO guidelines

• Age 18–65 years (case-by-case evaluation for adolescents ≥ 16 with severe comorbidities or adults > 65)

• Documented failure of at least 6 months of supervised non-surgical weight management

• Psychological clearance confirming absence of active untreated eating disorders (binge eating disorder requires pre-operative CBT), severe uncontrolled psychiatric illness, or active substance use disorder

• Motivation and ability to commit to lifelong nutritional supplementation (B12, iron, calcium with Vitamin D, folate) and post-operative follow-up

Required Pre-Operative Diagnostics:

• Complete metabolic panel: HbA1c, fasting insulin, HOMA-IR, lipid panel, thyroid function (TSH, Free T4)

• Hematological workup: CBC, iron studies (serum ferritin, TIBC), Vitamin B12, Vitamin D (25-OH), folate

• Cardiac assessment: 12-lead ECG; ECHO (2D echocardiogram) if BMI > 50, age > 45, or history of dyspnea/hypertension; stress test if indicated by RCRI ≥ 2

• Pulmonary: chest X-ray; formal polysomnography or WatchPAT home sleep study for OSA screening (STOP-BANG score ≥ 3)

• Upper GI endoscopy (EGD) to rule out H. pylori, GERD, Barrett's esophagus, or gastric pathology that may alter surgical planning

• Abdominal ultrasound to assess gallbladder (cholelithiasis is common in obese patients; concomitant cholecystectomy may be planned)

• Nutritional counseling session and baseline DEXA scan (optional but recommended for lean mass vs. fat mass baseline)

• Psychiatric/psychological evaluation (validated tools: Beck Depression Inventory, Binge Eating Scale)

Contraindications:

• Active malignancy undergoing treatment

• Severe portal hypertension or cirrhosis (Child-Pugh B/C)

• Uncontrolled severe psychiatric disorder (active psychosis, severe borderline personality disorder without specialist clearance)

• Active substance abuse (alcohol, opioids) within 12 months

• Pregnancy or planning pregnancy within 18 months post-surgery

• Severe GERD with large hiatal hernia may favor sleeve gastrectomy over bypass in select cases (though RYGB also treats GERD — surgeon judgment required)

• Inability to comply with lifelong nutritional follow-up

Gastric bypass surgery encompasses several technique variations and technological platforms. Understanding the differences helps patients and referring physicians select the most appropriate approach.

1. Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) — The Gold Standard

The most commonly performed bariatric procedure globally. Using 5–6 small port incisions (5–12 mm), the surgeon creates a 15–30 mL proximal gastric pouch using a linear endoscopic stapler (e.g., Medtronic Signia or Ethicon Echelon series). The small bowel is divided approximately 30–50 cm from the ligament of Treitz; the Roux limb (typically 100–150 cm) is brought up to anastomose with the gastric pouch (gastrojejunostomy), while the biliopancreatic limb (50–75 cm) is joined distally (jejunojejunostomy). The anastomoses are fashioned using circular staplers (21–25 mm EEA) or linear staplers with hand-sewn oversewing. Intraoperative leak test is mandatory (methylene blue or endoscopic insufflation). Operative time: 90–150 minutes. This approach reduces hospital stay to 3–5 days and recovery time to 3–4 weeks versus 6–8 weeks for open surgery.

2. Robotic-Assisted Roux-en-Y Gastric Bypass (RRYGB) — Advanced Platform

Performed using the da Vinci Xi or da Vinci SP surgical system (Intuitive Surgical), robotic assistance provides 3D high-definition magnified visualization, 7-degrees-of-freedom EndoWrist instrumentation, and tremor filtration. This platform is particularly advantageous for: (a) super-obese patients (BMI > 55) with increased abdominal wall thickness limiting laparoscopic triangulation; (b) revisional bariatric surgery (conversion from sleeve gastrectomy or failed adjustable gastric band); and (c) complex anastomotic fashioning in confined anatomical spaces. Robotic RYGB is associated with lower anastomotic leak rates (1.2% vs. 2.1% in laparoscopic series in high-volume centers) and reduced conversion to open surgery. Available at premium JCI-accredited centers in Mumbai, Chennai, Delhi (India) and Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai (UAE).

3. One-Anastomosis Gastric Bypass (OAGB) / Mini Gastric Bypass

A simplified two-anastomosis-free technique (one gastrojejunostomy, no jejunojejunostomy) gaining IFSO recognition as an acceptable primary procedure. Faster operative time (60–90 min), comparable weight loss to LRYGB, but carries a theoretical risk of bile reflux gastritis. Suitable for patients prioritizing shorter operative time or with prior abdominal surgery limiting bowel mobilization. Less commonly offered for primary cases in high-volume Indian and UAE centers, where LRYGB remains preferred.

4. Revisional Bariatric Surgery

Conversion of failed or complicated prior bariatric procedures (e.g., sleeve gastrectomy with weight regain, gastric band erosion or slippage) to RYGB. Technically demanding — robotic assistance is strongly preferred. Requires thorough pre-operative imaging (CT abdomen with oral contrast, upper GI series) and EGD.

5. Adjunctive Technologies & Protocols

• Enhanced Recovery After Bariatric Surgery (ERABS) protocol: multimodal analgesia (TAP blocks, ketamine, IV acetaminophen), early ambulation (within 6 hours post-op), and same-day liquid diet initiation reduce hospital stay and opioid consumption.

• Intraoperative endoscopy: simultaneous EGD during RYGB to assess anastomotic integrity.

• ICG (Indocyanine Green) fluorescence imaging: used in robotic cases to assess anastomotic perfusion and reduce leak risk.

• Continuous glucose monitoring (CGM) integration: post-operative glycemic management using CGM devices (e.g., Abbott FreeStyle Libre) for diabetic patients.

• Pharmacological bridging: patients on GLP-1 receptor agonists (semaglutide/Ozempic) must discontinue 2 weeks pre-operatively to reduce aspiration risk from delayed gastric emptying.

Phase 1 — Pre-Operative Preparation (4–8 Weeks Before Surgery)

• GAF Healthcare assigns a dedicated patient coordinator who collects all prior medical records, imaging, and labs for remote review by the treating bariatric surgeon.

• Virtual consultation (video call) with the surgeon and bariatric dietitian to review candidacy, set weight-loss goals, and begin a 2–4 week pre-operative liver-shrinking diet (high-protein, low-carbohydrate, 800–1,200 kcal/day) to reduce liver volume by 15–20%, improving intraoperative visualization.

• GLP-1 agonists (if prescribed) discontinued 2 weeks before surgery. Antidiabetic medications and anticoagulants adjusted per anesthesia protocol.

• E-Medical visa application (India) or tourist/medical entry visa (UAE) facilitated by GAF Healthcare's visa team.

• Pre-operative labs, ECG, ECHO, polysomnography, and EGD completed locally or on arrival at the partner hospital.

Phase 2 — Arrival & Admission (2–3 Days Before Surgery)

• GAF Healthcare airport pickup with dedicated coordinator. Transfer to partner hospital or pre-arranged accommodation.

• Anesthesia pre-assessment clinic: airway assessment (Mallampati scoring, neck circumference), DVT risk stratification (Caprini score — most bariatric patients are high risk, requiring pharmacological prophylaxis with LMWH + sequential compression devices).

• Surgeon marks operative site; consent obtained. Bowel prep not routinely required for RYGB.

• Admission day: IV access, LMWH administered, compression stockings fitted. NPO (nil per os) from midnight.

Phase 3 — Surgery Day

• General anesthesia with rapid sequence induction (RSI) protocol due to high aspiration risk; video laryngoscopy (C-MAC or GlideScope) on standby for difficult airway.

• Patient positioned in reverse Trendelenburg (20–30°) to optimize diaphragmatic excursion.

• Laparoscopic or robotic ports placed; pneumoperitoneum established.

• Gastric pouch creation → Roux limb measurement → gastrojejunostomy → jejunojejunostomy → intraoperative leak test → port closure. Duration: 90–150 minutes.

• ICU/HDU observation for 12–24 hours post-operatively (standard for high-BMI patients; step down to ward if vitals and drain output stable).

Phase 4 — In-Hospital Recovery (Days 1–5)

• Day 1: Early ambulation (walking within 4–6 hours). Clear liquid diet commenced (30 mL/hour sips). Pain managed with IV acetaminophen + ketorolac ± low-dose opioid rescue. LMWH continued.

• Day 2: Gastrografin swallow study or CT with oral contrast to confirm anastomotic integrity (protocol varies by center). Advance to full clear liquids. Respiratory physiotherapy (incentive spirometry).

• Day 3–4: Advancement to pureed/protein shake diet. Oral medications resumed. Drain removal if output < 30 mL/24h and no bile staining. Bariatric dietitian review: protein target 60–80 g/day minimum.

• Day 5: Discharge criteria met — tolerating liquids, ambulating independently, pain controlled on oral analgesics, no fever or tachycardia.

Phase 5 — Post-Discharge Recovery (Weeks 1–4)

• Weeks 1–2: Rest at GAF Healthcare-arranged accommodation near the hospital. Daily wound check by home-visit nurse or outpatient clinic. Diet progresses: clear liquids → full liquids → pureed → soft foods.

• Week 2–3: Follow-up appointment with surgeon; suture/staple removal if non-absorbable. Blood work: CBC, metabolic panel, glucose. CPAP therapy continued if OSA documented.

• Week 3–4: Patients cleared for air travel by the operating surgeon when: (a) no active wound complications, (b) tolerating soft diet without nausea/vomiting, (c) ambulating well (DVT risk substantially reduced), and (d) no fever or signs of anastomotic leak. Long-haul flights (> 6 hours) require continued LMWH prophylaxis on travel day.

• Fitness to fly: typically 3–4 weeks post-operatively.

Phase 6 — Long-Term Recovery & Follow-Up (Months 1–24)

• Month 1: Soft to regular diet progression. Begin moderate exercise (walking 30 min/day). Continue all bariatric supplements.

• Month 3: Significant weight loss milestone (20–30% EWL). Antidiabetic medications often dose-reduced or discontinued under physician guidance.

• Month 6: 50–60% EWL typical. DEXA scan to assess lean mass preservation. Nutritional labs reviewed.

• Month 12: 70–80% EWL. Skin redundancy assessment; body contouring consultation if desired.

• Month 18–24: Weight stabilization. Long-term supplement adherence and annual lab monitoring required indefinitely. GAF Healthcare facilitates telemedicine follow-up with the operating surgical team for international patients.